Cytosorbents Q4 EPS Forecast Increased by Zacks Small Cap

Cytosorbents Corporation (NASDAQ:CTSO) – Research analysts at Zacks Small Cap increased their Q4 2025 EPS estimates for Cytosorbents in a research note issued to investors on Tuesday, January 13th. Zacks Small Cap analyst T. Kerr now forecasts that the medical research company will earn ($0.04) per share for the quarter, up from their previous estimate of ($0.05). The consensus estimate for Cytosorbents’ current full-year earnings is ($0.30) per share. Zacks Small Cap also issued estimates for Cytosorbents’ FY2026 earnings at ($0.08) EPS.

Other research analysts have also recently issued research reports about the company. HC Wainwright cut their price target on Cytosorbents from $1.00 to $0.75 and set a “neutral” rating on the stock in a research note on Friday, November 14th. D. Boral Capital restated a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a report on Monday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cytosorbents in a research note on Friday, January 9th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Cytosorbents has an average rating of “Hold” and a consensus price target of $5.38.

Cytosorbents Stock Performance

NASDAQ:CTSO opened at $0.69 on Thursday. The firm has a 50-day moving average of $0.70 and a two-hundred day moving average of $0.86. The company has a debt-to-equity ratio of 1.61, a current ratio of 2.11 and a quick ratio of 1.71. The stock has a market cap of $43.38 million, a P/E ratio of -3.84 and a beta of 1.32. Cytosorbents has a 1-year low of $0.60 and a 1-year high of $1.61.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings results on Thursday, November 13th. The medical research company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. Cytosorbents had a negative net margin of 27.77% and a negative return on equity of 101.14%. The business had revenue of $9.49 million during the quarter, compared to analyst estimates of $10.02 million.

Institutional Investors Weigh In On Cytosorbents

Several institutional investors and hedge funds have recently bought and sold shares of CTSO. Goldman Sachs Group Inc. boosted its stake in Cytosorbents by 149.2% in the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after acquiring an additional 37,519 shares during the period. CIBC Bancorp USA Inc. acquired a new stake in shares of Cytosorbents during the 3rd quarter worth approximately $161,000. Avenir Corp lifted its holdings in shares of Cytosorbents by 0.3% in the 2nd quarter. Avenir Corp now owns 5,058,537 shares of the medical research company’s stock worth $6,475,000 after purchasing an additional 13,619 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of Cytosorbents in the 3rd quarter worth approximately $105,000. Finally, Vanguard Group Inc. boosted its position in Cytosorbents by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock valued at $2,059,000 after purchasing an additional 79,535 shares during the period. Institutional investors and hedge funds own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.